Introduction
Type I diabetes is an autoimmune illness characterized by destruction of insulin-producing pancreatic beta cells, resulting in insulinopenia, hyperglycemia and in the development of chronic complications. Optimal treatment should provide a physiological insulin replacement with post-prandial insulin peaks and constant basal levels during fast and at night. The most common treatment modality is based on the exogenous administration of the hormone through multiple daily injections (MDI). Although this intensive regimen delays the onset and slows the progression of diabetic complications, 1 it is cumbersome, is accepted only by a minority of patients 2 and is associated with a high risk of hypoglycemic events. 3 A different way to provide basal insulin levels relies on continuous subcutaneous insulin infusion through programmable external pumps, which are indeed associated with better glycemic control and lower incidence of hypoglycemia as compared with MDI. 4 However, problems related to management, acceptability and costs further reduce the use of this kind of treatment. [5] [6] [7] Correspondence: S Martinenghi, Alternative therapeutic approaches based on allogenic transplantation are indeed a clinical option, but only in selected cases. Pancreas transplantation is able to completely normalize glucose metabolism, but is a major surgical procedure and requires permanent immunosuppression, 8 which is associated with increased risk of cancer 9 and infections. 10, 11 The less invasive human islet transplantation has been shown to be successful in a specific setting, although still requiring immunosuppression and two/three donor pancreata per recipient. 12, 13 Considering the high number of affected patients worldwide, 14, 15 human organ shortage represents the major limitation to the extension of transplantation to the large diabetic population.
A completely different approach to the treatment of the disease is represented by somatic gene therapy, in which non-beta cells are engineered for the production, processing and secretion of insulin. To be translated into a therapeutic option, gene therapy should rely on a safe procedure targeted at an accessible site, where possibly repeated interventions could be performed for optimal dosage.
Among the candidate tissues to be engineered for insulin secretion, the skeletal muscle could be a promising site. The muscle is able to secrete several proteins into the bloodstream after gene transfer through both viral DNA and express it for a long time after simple plasmid injection. 22 This function seems to be a special feature of adult muscle cells, and may be due to muscle's postmitotic state. 23, 24 Moreover, the large tissue mass, its easy accessibility and the possibility to repeat injections at different sites make the skeletal muscle a unique tissue for the transfer of therapeutic genes. Although simple DNA injection into muscle is associated with low levels of expression, in vivo electroporation (ET) can enhance the levels of transgene expression by 1-2 logs. 25, 26 Different ET protocols have been employed by several groups to induce the secretion of proteins from the muscle in mice, rats, rabbits, monkeys and piglets. [27] [28] [29] However, ETinduced gene transfer is known to be associated with a certain degree of muscular damage induced by the electric pulses, 28, 29 resulting in inflammation and possibly immune reaction against the transgene.
In the present study we have established an optimized ET protocol which leads to minimal muscular damage. Using this protocol we injected two plasmids carrying a furin-cleavable proinsulin cDNA under the control of two different promoters. This transfer approach resulted in consistent levels of mature human insulin, which were able to prolong survival and correct fasting blood glucose (BG) in mice with severe diabetes.
Results

Insulin and C-peptide release by C2C12 myotubes
As muscle cells lack specific convertases for the cleavage of proinsulin to mature insulin and C-peptide, we have employed a mutated human proinsulin cDNA carrying two consensus sequences for the ubiquitous protease furin (FurHPI). 30, 31 Two plasmids carrying the FurHPI cDNA under the transcriptional control of either the CMV or the MFG promoter were functionally evaluated in transfection experiments in the mouse skeletal muscle cell line C2C12. To be more representative of adult muscle, cells were induced to fuse by serum deprivation. Insulin and C-peptide accumulated in the culture media from 7-day fused myotubes: CMV: insulin 24.4 ± 3.4 pmol/l, C-peptide 83.3 ± 3.3 pmol/l; MFG: insulin 249.9 ± 70.8 pmol/l, C-peptide 1293.3 ± 336.3 pmol/l; mock: insulin Ͻ3.6 pmol/l, C-peptide Ͻ23.3 pmol/l. In a separate transfection experiment performed in the same conditions with the MFG construct, the amount of proinsulin was also evaluated to calculate the percentage of processing: insulin 153.6 ± 17.8 pmol/l, C-peptide 830.0 ± 94.2, proinsulin 1103.0 ± 65.5 pmol/l. As proinsulin is cleaved to one mole of insulin and one mole of C-peptide, the percentage of human proinsulin processed can be calculated either on insulin or on C-peptide, and is 12% when calculated on insulin and 43% when calculated on C-peptide. The apparent discrepancy between the molar amounts of insulin and C-peptide produced could be due to utilization of insulin by myocytes.
Establishment of an efficient ET protocol associated with a low degree of muscular damage
The characteristics of the electric field associated with both transfection efficiency and limited muscular damage have not been defined yet. Therefore, we have evaluated three different ET protocols (see Materials and methods) after intramuscular injection of a CMV-LacZ-carrying plasmid in mice. To test the current parameters associated with the best ratio between transfection efficiency and muscular damage, 100 g (in 50 l) of plasmid were injected in one site of mouse tibialis anterior (TA) or quadriceps (Q) muscle; electric pulses were then applied. One week after injection, all protocols were associated with a high number of transfected myofibers, exhibiting a medium or intense ␤-gal staining. For each protocol, electrodes were placed either transcutaneously or on the surgically exposed muscle, and no difference was observed between these two modalities. The distribution of transfected cells extended throughout the whole length of the muscle. Within the single transverse section, transfected cells were often localized at one extremity in the Q muscle, while being more diffuse in the TA muscle. The number of ␤-gal positive cells was higher with protocols 1 and 3. Protocol 1 was also associated with the lowest degree of muscular damage. Indeed, the frequency of necrotic areas, the extension of the lesions and the amount of infiltrating inflammatory cells were all reduced with protocol 1 as compared with the other two protocols. Results obtained with the three ET procedures are summarized in Table 1 . In the TA muscle, a mean of 105 ± 40 transfected cells/section out of an approximate total number/section of 1000 was counted, thus representing an average transfection efficiency of 10%; however, a large variability was observed: range: 20-220 blue cells, ie 2-22%/section. Histological pictures representative of the three protocols are shown in Figure 1 . Figure 2 shows ␤-gal and hematoxylin-eosin staining 1 week after DNA injection alone and 1 and 4 weeks after injection + ET protocol 1. As a second parameter of transfection efficiency, the levels of transgene expression were quantified. ␤-Galactosidase activity was determined on muscle extracts 1 week after plasmid injection + ET for comparison of the three protocols. Data, which are summarized in Figure 3 , have shown a trend for a higher activity with protocols 1 and 2 as compared with 3, although not at the statistical level. A high variability was confirmed.
As a serum marker of muscular damage, circulating levels of CPK were evaluated in untreated mice at 2 and at 24 h after plasmid injection and ET with three different protocols. Positive controls were represented by mice in which muscular damage was induced by injection of cardiotoxin. At 2 h after ET, CPK levels were elevated in all ET groups, although only levels observed after ET 1 were significantly lower as compared with positive controls. At 24 h, CPK values were nearly normal with no difference between protocols ( Figure 4 ).
For the reasons of good efficiency and low toxicity, ET protocol 1 with transcutaneous electrodes was selected for subsequent in vivo experiments with insulin encoding plasmids.
Secretion of human insulin into the circulation after injection + ET
A first group of 10 mice was injected with the pGL3-CMV-FurHPI plasmid. In seven of 10 mice, circulating human insulin was detected at 2 weeks (mean ± s.e.: 12.9 ± 5.3 U/ml, range 1.0-42.3), completely disappearing at 4 weeks. However, RT-PCR analysis for human insulin in injected muscles was positive in eight of 10 mice killed at 4 weeks ( Figure 5 ). The MFG-FurHPI construct was tested in vivo in a second series of 10 animals, as data in transfected C2C12 myotubes indicated that the MFG and in the Q (quadriceps) muscles out of 1000 counted cells. n denotes the number of section analyzed. Six muscles were analyzed for each protocol, three for each modality (transcutaneous/exposed). TA versus Q: significant for all three protocols, both transcutaneous and exposed. a P = 0.0001 versus protocol 2; promoter was associated with a higher hormone production as compared with the CMV promoter. In all mice, insulin was detectable at a mean ± s.e. concentration of 68.5 ± 34.9 U/ml (n = 10, range 1.1-248.2) at 1 week, declining at 20.3 ± 14.4 U/ml (n = 9, range 1.1-125.6) at 2 weeks. Insulin persisted in all animals at 4 weeks (n = 9, 7.7 ± 2.6 U/ml, range 1.1-24.3). After 6 weeks, insulin was still present in four of nine mice (4.4 ± 1.7 U/ml, range 1.1-7.7), disappearing at 8 weeks ( Figure 6 ). Control animals (untreated diabetics and CMV-␤-injected) had human insulin levels Յ0.6 U/ml.
Increase of survival in diabetic treated mice
Mice injected with the pGL3-CMV-FurHPI DNA maintained a stable body weight up to death 4 weeks after gene electrotransfer. Among mice injected with the pGL3-MFG-FurHPI DNA, one died 10 days after injection; the other nine mice showed a stable body weight Gene Therapy with an increase at weeks 3 and 4 after treatment, and a subsequent decline thereafter. These animals survived up to 10 weeks post-ET, four additional weeks after serum insulin disappearance. Diabetic control animals (n = 10) died or had to be killed within 3 weeks after STZ, with a rapid decline in body weight ( Figure 7 ).
Reduction/normalization of blood glucose levels
In the CMV group of mice, average fed BG was unchanged during the 4 weeks follow-up. On the contrary, in concomitance with the serum insulin peak, MFG-injected mice showed a significant reduction of fed BG levels as compared with pre-treatment values, although remaining in the hyperglycemic range (mean ± s.d.: from 418.1 ± 85.6 to 310.7 ± 107.6, P = 0.001).
To evaluate if insulin levels achieved with plasmid ET were able to control fast BG, a 15-h fasting test was performed. The CMV group, tested 2 weeks post ET with insulin levels of 12.9 ± 5.3 U/ml, showed a significant BG reduction from (mean ± s.e.) 471.9 ± 9.3 to 150.9 ± 13.5 mg/dl. Similarly, the MFG group, tested 4 weeks post ET with insulin levels of 7.7 ± 2.6 U/ml, significantly reduced BG from 527.7 ± 24.9 to 139.3 ± 16.2 mg/dl. For comparison, a separate group of five untreated diabetic mice was tested 1 week after STZ, when overtly diabetic but before cachexia ensued. Fast BG levels decreased also in this group as compared with fed BG (from 521.8 ± 33 to 262.6 ± 51 mg/dl), but remained significantly higher as compared with both groups of treated mice (P = 0.015) (Figure 8, upper panel) . The BG levels obtained in fasted MFG mice (139.3 ± 16.2 mg/day) were comparable to random BG observed in fed non-diabetic control mice (107.3 ± 7.8 mg/dl, P = NS).
Absence of hypoglycemia upon prolonged fasting
In order to verify if insulin levels of 7.7 ± 2.6 U/ml exposed animals injected with the MFG-FurHPI plasmid to the risk of hypoglycemia, a prolonged (24-h) fasting was performed between 4 and 5 weeks after ET. Insulin-ET mice progressively reduced their BG levels, reaching the values observed in non-diabetic controls after 16-20 h. No severe (Ͻ50 mg/dl) hypoglycemia developed both in treated and in control mice (Figure 8, lower panel) .
Discussion
The development of an alternative source of insulin through a clinically acceptable gene transfer procedure would clearly represent a valuable therapeutic option for ) have been explored as targets for insulin gene therapy: among these, the skeletal muscle offers the advantage of the large mass, the ease of an external access through minimally invasive procedures and the possibility of multiple and repeated injections. Previous work showed that muscle cells in culture are able to release (pro) insulin-related proteins and to process a part of those products into mature insulin after transfer of a FurHPI gene. 37, 38 Similar results were obtained in our study, where C2C12 myotubes were used as a model of adult muscle cells. Upon transfection with two FurHPIGene Therapy expressing plasmids, discrete amounts of mature insulin and C-peptide were detected in the culture medium. We then tested whether the skeletal muscle can be engineered for the release of mature human insulin in vivo.
Figure 4 Serum CPK levels at 2 and at 24 h after plasmid injection + ET protocols 1, 2, 3 (n = 4 each). Uninjected mice, negative controls (NC) (n = 3), positive controls (PC) (n = 3). t-test at 2 h post-ET
Among gene transfer procedures, plasmid DNA intramuscular injection + ET was investigated, based on its reported efficiency to induce protein secretion and its potential advantages over viral methods. Several ET protocols have been described, 25, 26, 29 all of them being associated with a gain in transfection efficiency as compared with DNA injection alone. However, the ET procedures reported so far are associated with some degree of muscular damage. 39, 40 The muscular damage and the associated inflammatory infiltrate might induce an immune reaction against the injected plasmid and therefore reduce the level and the duration of gene expression. The identification of electrical parameters associated with a limited degree of muscular damage could limit the inflammatory infiltrate, thus preserving transfected fibers from destruction and possibly resulting in higher and longer transgene expression. In this work, we have evaluated by histologic analysis three ET protocols among which one was found to be associated with minimal muscular damage at 1 week. Moreover, at 2 h this protocol induced an elevation in serum CPK levels which was limited as compared with the other two protocols.
Electrotransfer-enhanced muscle gene transfer of two plasmids carrying a FurHPI gene resulted in the release of significant amounts of mature human insulin in the serum of treated animals. When the MFG promoter was used, a longer duration of expression could be obtained as compared with the CMV promoter, indicating that the transcriptional regulation can influence the duration of expression. The utilization of a muscle-specific promoter, either naturally occurring or synthetic, might provide a further advantage. 41, 42 The most striking effect of FurHPI gene transfer was Gene Therapy an increase in animal survival. All diabetic control mice died or had to be killed within 3 weeks after STZ. In contrast, all but one treated mouse maintained body weight and survived up to 10 weeks after ET (MFG group). The levels of circulating insulin, although not able to correct diabetes in the fed state, were clearly sufficient to prolong survival. A similar beneficial effect was recently reported by Yin and co-workers, 34 who showed a significant reduction in the mortality rate of severely diabetic mice after injection of human proinsulin DNA. No difference in survival and BG was observed between wild-type proinsulin and a proinsulin cDNA carrying one furin-cleavage site for processing to mature insulin, suggesting that wild-type proinsulin, despite its low biological activity, can prolong survival. However, in that study results can not be correlated to insulin/proinsulin levels, since the assay used did not discriminate between mouse and human and between unprocessed and processed insulin forms. In another work, 43 processed proinsulin was detected in mouse muscle extracts co-injected with a rat proinsulin DNA bearing two furin-cleavage sites and with a furin DNA plasmid. The advantage of furin coexpression on insulin release was, however, not clear, since the authors did not report blood insulin levels. In our study, a FurHPI gene carrying two mutations for furin cleavage at both the C-peptide-A chain and C-peptide-B chain of the proinsulin molecule was used, and a specific assay for fully processed insulin, reacting neither with proinsulin nor with mouse insulin, was employed. Results showed that mature human insulin was consistently detected in the serum of treated animals, providing the first evidence of circulating mature insulin after intramuscular plasmid injection + ET.
An effect of circulating insulin on BG levels was also observed. In MFG-injected mice with free access to food, fed BG was reduced, although not to normal levels, in correspondence with the serum human insulin peak of 68.5 ± 34.5 U/ml. This value, although similar to mouse insulin levels of a separate group of five non-diabetic, uninjected nude mice (49.3 ± 8.1 U/ml), was not able to normalize fed BG, possibly due to insulin resistance. 44 A similar partial effect of physiological insulin levels was also described in another mouse strain (Balb/c) with STZ-induced diabetes. 20 When mice were fasted for 15 h, treated animals showed a lowering of BG levels, reaching values significantly different from those observed in fasted diabetic untreated mice. Basal insulin levels of 7.7 ± 2.6 U/ml (MFG group), albeit not able to control hyperglycemia in mice with free access to food, were suf- ficient to correct BG, provided discontinuation of food assumption. Moreover, these insulin levels appeared to be safe, as hypoglycemia was not observed even upon prolonged (24-h) fasting. For comparison with the physiological situation, mouse insulin levels were determined in the above-mentioned group of five nondiabetic nude mice after a 15-h and a 24-h fasting, and were: 4.3 ± 1.4 and 11.8 ± 1.2 U/ml, respectively. After STZ-induced diabetes, mouse insulin levels dropped to 3.9 ± 1.3 U/ml in the fed state. In conclusion, ET optimization lead to low muscular damage. The injection of a FurHPI encoding plasmid produced consistent levels of circulating mature human insulin, with a significant increase in survival and a complete correction of fast BG.
A number of caveats should be solved before clinical application of this approach: the large interindividual variability in the levels of the secreted protein, especially at the peak, the relative short duration of transgene expression, and the lack of regulation in insulin secretion.
Although the ultimate goal of diabetes gene therapy is to completely replace exogenous insulin treatment, a first relevant objective is the restoration of basal insulin levels Gene Therapy to cover for night and fasting periods. Providing diabetic patients a basal insulin and C-peptide secretion within a safety range could be indeed beneficial to glucose control. 45 In this perspective, a non-viral DNA gene transfer to the skeletal muscle appears a promising approach.
Materials and methods
Expression plasmids
Three expression plasmids were used: pCMV-␤, pGL3-CMV-FurHPI, pGL3-MFG-FurHPI. The pCMV-␤ plasmid (Clontech, Palo Alto, CA, USA; Genbank accession No. U02451) contained the human immediate-early cytomegalovirus promoter (CMV IE) upstream of the LacZ gene (E. coli ␤-galactosidase). The pGL3-CMV-FurHPI plasmid was generated after removing the Luciferase gene and cloning a 365-bp furin-cleavable human proinsulin cDNA (FurHPI) 31 into the NcoI-XbaI sites of the pGL3 basic vector (Promega, Madison, WI, USA). In this plasmid, the human CMV promoter (excised from pcDNA 3, Invitrogen, Gibco, Carlsbad, CA, USA) was inserted into the BglII-HindIII sites (total plasmid size: 4387 bp). The pGL3-MFG-FurHPI plasmid was then generated by replacing the CMV promoter with the MFG promoter, a Moloney LTR promoter 46 (1849 bp, kindly provided by F Mavilio, San Raffaele Scientific Institute, Milan, Italy) into the NheI-NcoI sites (total plasmid size: 5311 bp). Plasmids were amplified in DH-5␣ cells and purified on Qiagen columns. Plasmid DNA was resuspended in sterile PBS at a concentration of 2 g/l and stored at Ϫ20°C.
In vitro transfection
Mouse C2C12 myoblasts were cultured in standard DMEM medium, supplemented with 10% fetal calf serum (FCS), 2 mM glutamine, penicillin and streptomycin. Cells were plated 1.5 × 10 5 /well in six multiwell plates, and transfected the day after with 2 g/well of plasmid DNA/FuGENE6 (Boehringer, Mannheim, Germany) for 5 h. Transfection efficiency was evaluated by pCMV-␤ transfection in parallel wells. After transfection, medium was changed to DMEM 2% FCS to induce fusion. Six days after culture in differentiation medium, 600 l of fresh medium was overlaid on cells and collected after 24 h for insulin and C-peptide determinations. Differentiation into myotubes was confirmed by morphological analysis.
In vivo gene transfer and electroporation procedures
Five-to 6-week-old male immunodeficient nude (nu/nu) mice (Charles River, Calco, Italy) were housed in the institutional animal facility and maintained on standard chow ad libitum. Mice were made diabetic by intravenous injection of streptozotocin (STZ), 150 mg/kg body weight (Sigma, St Louis, MO, USA). Animals were considered diabetic when blood glucose levels were Ն400 mg/dl, which occurred 5-7 days after STZ injection. One week after STZ, mice were anesthetized by inhaled fluothane, and plasmid DNA was injected into the tibialis anterior (TA) and quadriceps (Q) muscles with a 0.5-ml insulin syringe through a 27-gauge needle, in a constant volume of 50 l. Each animal received 200 ␥ of plasmid DNA (100 ␥/site). A pair of stainless steel plates was then applied over the muscle to encompass the injection area. In all cases the distance between the electrodes was 5 mm. Current was delivered 5 to 10 min after DNA injec-tion as a constant current, square-wave pulse with a digital Stimulator (Panlab 3100, Biological Instruments, VA, Italy) and checked by a digital oscilloscope (Tektronix TDS210, Beaverton, OR, USA). The characteristics of the electric field applied with the three tested protocols were: protocol 1: 200 V/cm, 1 ms amplitude, 10 Hz, nine consecutive pulses; protocol 2: 200 V/cm, 20 ms amplitude, 1 Hz, eight consecutive pulses; protocol 3: 100 V/cm, 200 s amplitude, 1 Hz, 10 pulses with 1 s interval. Protocols 2 and 3 have already been utilized by other groups. 20, 23 Protocol 1 has been empirically designed to have an amplitude and a frequency intermediate between the other two protocols. Each protocol was assayed both with the electrodes applied transcutaneously and on the exposed muscle. The animals were then kept warm until recovery. Animal studies were approved by the San Raffaele Institutional Animal Care and Use Committee (IACUC permission No. 90, 1999).
␤-Galactosidase assay
The entire tibialis and quadriceps muscle was removed surgically, frozen immediately on dry ice in 1.5-ml Eppendorf tubes and stored at Ϫ80°C. Muscle extraction was performed as described 47 . ␤-Galactosidase activity was detected by a colorimetric assay (GAL-A, Sigma, St Louis, MO, USA). Enzyme activity was assayed on 25 l of muscle lysate and expressed both as mU/muscle and as mU/100 g protein.
Blood glucose and CPK determinations
Blood was drawn from the tail vein after excision. Blood glucose levels (BG) were measured using a portable glucose tester (One Touch II, Lifescan; Johnson & Johnson, Milpitas, CA, USA; detection limits 0-600 mg/dl). Unless otherwise specified, BG was measured between 9 and 10 am in the fed state.
As a serum marker of muscular damage, 40 creatin-phosphokinase (CPK) levels were determined on 50 l of serum by an automated instrument (Modular, Hitachi, Tokyo, Japan) in untreated mice and at 2 and at 24 h after plasmid injection and ET with three different protocols. Positive controls were represented by mice injected with 100 l of cardiotoxin (Cytotoxin, Latoxan, Valence, France) 5 mM in the TA muscle. 48 Negative controls were uninjected mice.
Assays for human insulin and C-peptide and for mouse insulin
The first group of 10 mice injected with the CMV-FurHPI plasmid were bled at 2 and 4 weeks after gene transfer; the second group injected with the MFG-FurHPI plasmid were bled at 1, 2, 4, 6 and 8 weeks after gene transfer. Anesthetized mice were bled from the retroorbital plexus using a heparinized polyethylene tubing (PE 60, Becton Dickinson, Parsippany, NJ, USA). For human insulin determination, an immunoradiometric insulin assay (IRMA, Sanofi-Pasteur, Paris, France) was used on 100 l of serum. This assay employs a monoclonal antibody that recognizes mature human insulin and the split 65-66 only, does not cross-react with the other human forms, or with mouse insulin or proinsulin (Ͻ0.0001%, according to the provider). The sensitivity of the assay was 0.6 U/ml, and the interassay variation was Յ8%, according to the provider. The same assay was used for in vitro insulin determinations in C2C12 culture medium. For in vitro determinations of human C-peptide, a radioimmunoassay (Euro-DPC LTD, Llamberis, Gwynedd, UK) was employed on 200 l, with a sensitivity of 0.07 ng/ml. For mouse insulin determination in control non-diabetic mice and after STZ treatment, a radioimmunoassay was employed (Linco Research, Missouri, USA) with 100% sensitivity for mouse insulin.
RT-PCR analysis for human insulin expression
Muscles were harvested at death, frozen in liquid nitrogen and stored at Ϫ80°C until processed. Briefly, total RNA was extracted from muscle samples with Eurozol (EuroClone, Paignton, UK) after homogenization, and retrotranscribed using MoMLV Reverse Transcriptase (Gibco). Human insulin mRNA was amplified using AmpliTaq Gold DNA polymerase (Perkin Elmer, NJ, USA). Primer sequences were as follows: A: 5'-CCTTTGTGAACCAACACCTG-3' and B: 5'-CTGGTA-CAGCATTGTTCCAC-3' The RT-PCR products were analyzed by agarose gel electrophoresis.
Histochemical staining for ␤-galactosidase activity Tibialis anterior and quadriceps muscles were frozen in Tissue-Tek OCT compound (Sakura, The Netherlands). Cryostat serial sections (20 m) were cut and mounted on to glass slides. The slices were fixed in 4% paraformaldehyde, 4°C for 15 min, then washed in PBS and stained at 37°C for 3-5 h in X-Gal buffer (1 mg/ml 5 bromo-4-chloro-3-indolyl-␤-D-galactoside, 5 mM K 4 Fe(CN) 6 , 5 mM K 3 Fe(CN) 6 , 2 mM MgCl 2 in PBS). All positive cells were counted for each section analyzed. This count was performed on at least 20 sections/muscle.
Analysis of muscular damage
For the evaluation of muscle damage, 20 m cryostat sections were stained with hematoxylin-eosin. Sections were analyzed for the presence of cellular infiltrate and for signs of muscle cell damage, necrosis and regeneration, ie central nuclei.
Statistical analysis
For comparison within or between groups, two-tail Students' t-test was performed: a P value Ͻ0.05 was considered significant.
